Topical Imiquimod Treatment for Nodular Basal Cell Carcinomas

Nonsurgical Treatment Modalities for Primary Cutaneous Malignancies

“…Nodular BCCs were the focus of separate studies including an open‐label study by Huber and coworkers 69 and a randomized, open‐label, dose–response study by Shumack and coworkers 70 . Patients were followed for 6 to 12 weeks and 70% to 100% clearance was found in patients dosed at nightly applications of three times per week under occlusion (Huber) and nightly application seven times per week (Shumack).…”

Treatment of Basal Cell Carcinoma by Topical 25% Podophyllin Solution

“…Cure rate in the present study was 96% which is high, in comparison with other topical therapeutic modalities used in the treatment of basal cell carcinoma: as the treatment for nonaggressive subtypes of BCC with topical Imiquimod 5% cream have cure rates ranged from 60% to 100%, and this topical medication is approved by FDA only for superficial BCCs as large as 2 cm in diameter located on the neck, trunk, or extremities [29] [30]. while we using the topical podophyllin in all areas of the head, face, the neck, trunk, and the extremities.…”

“…Topical Imiquimod is approved by food and drug administration (FDA) only for superficial BCCs as large as 2 cm in diameter located on the neck, trunk, or extremities. Cure rates for nonaggressive subtypes of BCC have ranged from 60% -100% [29] [30]. Local side effects include erythema, hardened skin, edema, and vesiculation, and erosion, ulceration, scabbing, and flaking.…”

Topical and Intralesional Treatment of Nonmelanoma Skin Cancer: Efficacy and Cost Comparisons

“…There are studies indicating topical imiquimod and 5FU cream's effectiveness for other forms of NMSC. Clearance rates of imiquimod for the treatment of nodular and infiltrative basal cell carcinoma 6,8,9,13,[15][16][17][22][23][24][25] are shown in Table 1 and for the treatment of squamous cell carcinoma (SCC; in situ [26][27][28][29][30][31] and invasive SCC 30 ) and keratoacanthoma (KA) 32 are shown in Table 2. 5FU 5% cream has been studied in the treatment of SCC in situ.…”

“…For intralesional agents, the estimated cost of treatment includes the expense of intralesional injection of a chemotherapeutic agent for one to seven lesions (CPT codes 96405, $83.21) multiplied by the average number of treatments required and Once daily 15 78 (7/9) Geisse 10 Once daily 6 73 (130/179) Once daily, 5 d/wk 6 75 (139/185) Marks 11 Once daily 6 77 (86/111) Once daily, 5 d/wk 6 77 (75/97) Shumack 12 Once daily, 5 d/wk 6 83 (55/66) Peris 13 Once daily, 3 d/wk 12 91 (68/75) Schulze 14 Once daily 6 80 (67/84) Vun 15 Once daily 6 88 (14/16) Schiessl 16 Once daily, 5 d/wk 6 87 (13/15) Vidal 17 Once daily, 5 d/wk 5 100 (2/2) Once daily, 3 d/wk 8 100 (2/2) Gollnick 18 Once daily, 5 d/wk 6 80 (145/182) Quirk 19 Once daily 9 Once daily 14 100 (4/4) Huber 23 Once daily, 3 d/wk 12 100 (15/15) Peris 13 Once daily, 3 d/wk 12 53 (10/19) Vun 15 Once daily 6 100 (3/3) Eigentler 24 Once daily, 3 d/wk 10 57 (58/101) Leppala 25 Once daily, 5 d/wk 6 100 (4/4) Schiessl 16 Once the cost for excising recurrent lesions. The data for intralesional 5FU, MTX, and bleomycin are in Figure 2, and the data for the IFNs are displayed in Figure 3.…”